BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S. Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population. European Journal of Pharmacology 2013;710:80-4. [DOI: 10.1016/j.ejphar.2013.04.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Stack G, Maurice CB. Warfarin Pharmacogenetics Reevaluated: Subgroup Analysis Reveals a Likely Underestimation of the Maximum Pharmacogenetic Benefit by Clinical Trials. Am J Clin Pathol 2016;145:671-86. [DOI: 10.1093/ajcp/aqw049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Baranova EV, Verhoef TI, Asselbergs FW, de Boer A, Maitland-van der Zee A. Genotype-guided coumarin dosing: where are we now and where do we need to go next? Expert Opinion on Drug Metabolism & Toxicology 2015;11:509-22. [DOI: 10.1517/17425255.2015.1004053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
3 Nagler M, Angelillo-scherrer A, Méan M, Limacher A, Abbal C, Righini M, Beer JH, Osterwalder J, Frauchiger B, Aschwanden M, Matter CM, Kucher N, Cornuz J, Banyai M, Husmann M, Staub D, Mazzolai L, Hugli O, Rodondi N, Aujesky D. Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists. J Thromb Haemost 2017;15:2165-75. [DOI: 10.1111/jth.13810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
4 Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thrombosis Research 2014;134:537-44. [DOI: 10.1016/j.thromres.2014.05.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
5 Pai SA, Kshirsagar N. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts. J Clin Pharmacol 2016;56:1232-42. [PMID: 26873003 DOI: 10.1002/jcph.720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
6 Akdeniz CS, Cevik M, Canbolat IP, Yurdakul S, Cagatay P, Ciftci C, Karaalp A, Susleyici B. The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients. Future Cardiol 2020;16:645-54. [PMID: 32583677 DOI: 10.2217/fca-2020-0027] [Reference Citation Analysis]
7 Zhang J, Tian L, Zhang Y, Shen J. The influence of VKORC1 gene polymorphism on warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis. Thrombosis Research 2015;136:955-61. [DOI: 10.1016/j.thromres.2015.09.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
8 Qayyum A, Najmi MH, Mansoor Q, Farooqi ZU, Naveed AK, Hanif A, Kazmi SAR, Ismail M. Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population. Clin Appl Thromb Hemost 2017;23:800-6. [PMID: 27313202 DOI: 10.1177/1076029616654264] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Shah RR. Genotype‐guided warfarin therapy: Still of only questionable value two decades on. J Clin Pharm Ther 2020;45:547-60. [DOI: 10.1111/jcpt.13127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Gurusamy U, Shewade DG. Pharmacogenomics in India. Handbook of Pharmacogenomics and Stratified Medicine. Elsevier; 2014. pp. 1037-59. [DOI: 10.1016/b978-0-12-386882-4.00046-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Liu Y, Zhang R, Li Z, Zhou J, Yang T, Yang C, Huang X, Zhang Y, Shi S. Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep 2019;9:15774. [PMID: 31673051 DOI: 10.1038/s41598-019-51755-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Veeregowda SH, Krishnaswamy B, Balakrishna S. Effect of Vitamin K Epoxide Reductase Complex 1 Polymorphism on Warfarin Dose Requirement among Patients in Tertiary Care Hospital. Int J Appl Basic Med Res 2020;10:97-101. [PMID: 32566525 DOI: 10.4103/ijabmr.IJABMR_341_18] [Reference Citation Analysis]
13 Harikrishnan S, Koshy L, Subramanian R, Sanjay G, Vineeth CP, Nair AJ, Nair GM, Sudhakaran PR. Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population. Indian Heart J 2018;70 Suppl 3:S110-5. [PMID: 30595241 DOI: 10.1016/j.ihj.2018.07.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Gaikwad T, Shetty S, Ghosh K. Polymorphisms of warfarin metabolizing enzymes in an Indian population. Blood Cells Mol Dis 2013;51:203. [PMID: 23739742 DOI: 10.1016/j.bcmd.2013.05.004] [Reference Citation Analysis]
15 Saksena D, Mishra YK, Muralidharan S, Kanhere V, Srivastava P, Srivastava CP; VHD India consensus committee. Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario. Indian J Thorac Cardiovasc Surg 2019;35:3-44. [PMID: 33061064 DOI: 10.1007/s12055-019-00789-z] [Reference Citation Analysis]
16 Farzamikia N, Sakhinia E, Afrasiabirad A. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms. Laboratory Medicine 2018;49:25-34. [DOI: 10.1093/labmed/lmx072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
17 Gaikwad T, Shetty S, Ghosh K. Warfarin pharmacogenetics: How close are we to clinical practice? Indian J Hum Genet 2013;19:277-8. [PMID: 24339537 DOI: 10.4103/0971-6866.120806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Gaikwad T, Ghosh K, Avery P, Kamali F, Shetty S. Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. Clin Appl Thromb Hemost 2018;24:353-9. [PMID: 28049362 DOI: 10.1177/1076029616683046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]